The company announced yesterday that it had decided to appeal the Commercial Court's ruling in the case that has pitted it against Bpifrance since 2014.

Invest Securities confirms its neutral recommendation on the stock, with a target price of E3.3.

' Exactly 1 month ago, the company announced that the Montpellier Commercial Court had handed down a verdict in favor of Bpifrance, ordering Medesis
to pay E1.4m to Bpifrance ' recalls Invest Securities.

At the time, the company announced its intention to negotiate with Bpifrance management to identify a suitable repayment plan, but it seems that its intentions have changed, probably as a result of the discussions held. Medesis
now intends to appeal in order to obtain a reversal of the Court's decision, and to avoid the payment of 1.4mE, which represents a significant sum on the scale of Medesis' indicates the research firm.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.